Schizophrenia-Like Behavior In Rats Blocked Via Glutamate

August 28, 1998

An unexpected clue from a rat model of psychosis has led National Institute of Mental Health grantees to propose a new strategy for treating schizophrenia. Scientists have known for some time that the psychosis-inducing drug PCP (phencyclidine) blocks activation of receptors for the brain messenger chemical glutamate while stimulating activation of brain dopamine systems. Current antipsychotic drugs act by reducing dopamine activity.

When Dr. Bita Moghaddam and Barbara Adams of Yale University injected rats with PCP, they expected to see glutamate activity plummet as levels of dopamine soared. Instead, they found that doses of PCP that produced psychosis-like symptoms also increased glutamate levels. The PCP-induced neurotransmitter changes were accompanied by a characteristic pattern of aberrant running and head-turning behaviors and working memory impairments in the animals, which mimics some symptoms of schizophrenia.

Might this psychotic-like behavior be prevented by quenching glutamate? To find out, the researchers targeted a glutamate receptor subtype, known to fine-tune the neurotransmitter's activity, using an experimental compound (LY354740) under development by Eli Lilly & Co. The compound attenuates and normalizes glutamate activity by stimulating these presynaptic receptors, located on nerve terminals of glutamate-secreting neurons. In rats pretreated with the Lilly compound, PCP failed to trigger the behavioral abnormalities, cognitive impairments, or glutamate increases in the prefrontal cortex.

Affecting about 1 percent of adults, schizophrenia is the most chronic and disabling mental illness. It typically begins as a psychotic episode in early adulthood, with devastating hallucinations, delusions, social withdrawal, blunted emotionality, and loss of social and personal care skills. A new generation of antipsychotic medications (clozapine, risperidone, olanzapine, etc.) has helped many patients manage their most flagrant symptoms with fewer side effects. However, even the newer antipsychotics act on brain dopamine receptors, albeit more selectively, and often fail to have much effect on the "negative" cognitive and emotional symptoms of the disorder. Hence, there is a need to develop medications, such the novel glutamate compound, with different mechanisms of action.

Moghaddam and Adams report their results in the August 28 Science.

The National Institute of Mental Health (NIMH) is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services.
-end-


NIH/National Institute of Mental Health

Related Schizophrenia Articles from Brightsurf:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.

Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.

Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.

New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.

Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.

Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.

The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.

Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.

Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.

Read More: Schizophrenia News and Schizophrenia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.